DelveInsight’s, “Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors-Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors.
Note: This report will be delivered to the client in 48 hours
Report Highlights: The new report, provides a Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors Landscape across the globe The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages Coverage of the Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type The report reviews key players involved in the therapeutics development for PCSK-9 Inhibitors and also provide company profiling Pipeline products coverage based on various stages of development from NDA filings to discovery. Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.